bluuebunny/crossref_metadata_2025_split huggingface dataset:
A summer camp for children with cancer
Authors: Hvizdala Eva V. , Miale Thomas D. , Barnard Patricia J. 
Published: February 2007

AbstractThe prognosis for children with cancer has changed significantly over the past 10 years. Currently, it is anticipated that cure can be achieved in approximately 50% of newly diagnosed cases of childhood cancer. The quality of life for these children depends not only on their medical treatment but also on the successful management of the psychological problems related to their diagnosis.A summer camp was established in Florida as a part of our psychosocial rehabilitation program for pediatric cancer patients. Participating in the day‐today camp life were 26 children with various forms of cancer. Each child not only had the opportunity to enjoy a normal out‐of‐door life style, away from their overprotective parents, but experienced daily contact with other children who shared a similarly stressful existence. It is felt the awareness gained through the realization that they were not alone in their plight and the independence instilled through separation from parents was beneficial to each child.It is anticipated that future camps with the inclusion of psychological testing will provide us with the opportunity to further assess the need for psychosocial rehabilitation for the child with cancer.
Blastic transformation in chronic myelogenous leukemia: Experience with 50 patients
Authors: Marks Stanley M. , McCaffrey Ronald , Rosenthal David S. , Moloney William C. 
Published: February 2007

AbstractFifty consecutive patients with blastic chronic myelogenous leukemia were evaluated clinically, morphologically, biochemically, and therapeutically. Forty‐five patients had a preceding stable phase (38 Ph +, 7 Ph ‐); five patients presented with de novo Ph+ blast crisis. The most frequent clinical signs of impending blast crisis were weakness, fatigue, increasing splenomegaly, anemia, thrombocytopenia, marrow fibrosis, and a rising neutrophil alkaline phosphatase. Fever (unrelated to infection), skin infiltration, lymphadenopathy, hepatomegaly, thrombocytosis, and basophilia were much less common. The development of aneuploidy occurred in less than one‐half of the total group. Myeloblastic morphology at blastic transformation was most frequent with occasional lymphoblastic, promyelocytic, and undifferentiated cases seen. Terminal deoxynucleotidyl transferase was present in one‐third of the patients, but had no clear‐cut relationship to the morphology. Response to treatment was generally disappointing (two complete and 15 partial remissions in 45 treated patients).
Improvement in complete response rate, duration of response and survival with adriamycin combination chemotherapy for non‐Hodgkin lymphoma: A prognostic factor comparison of two regimens
Authors: Cabanillas Fernando , Rodriguez Victorio , Freireich Emil J. 
Published: February 2007

AbstractThe results of a chemotherapy regimen utilizing adriamycin in combination with vincristine, prednisone plus or minus cyclophosphamide (CHOP‐HOP) for the treatment of non‐Hodgkin lymphoma are compared to those of a non‐adriamycin containing combination (COP). The complete remission (CR) rate of 67% for CHOP‐HOP in malignant lymphoma, diffuse histiocytic type (MLDH) is superior to 33% obtained with COP. In malignant lymphoma, nodular poorly differentiated lymphocytic (MLNPD), the CR rate was: CHOP‐HOP 83%, COP 44%. The prognostic factors for both treatment groups were compared and found to be similar. Thus, adriamycin appears to be responsible for this improvement in CR rate. When analyzed as a group, the patients treated with CHOP‐HOP had a longer survival than those treated with COP. This difference was also evident in the subgroup of patients with MLDH. The smaller subgroup of patients with MLNPD treated with CHOP‐HOP did not show a significant improvement in survival. A trend for longer duration of CR in both diffuse and nodular lymphomas was also observed, but this difference did not reach statistical significance possibly due to the smaller numbers of patients. Combination chemotherapy with adriamycin has resulted in a higher CR rate and survival for patients with non‐Hodgkin lymphoma particularly for the subgroup of patients with MLDH.
Alpha‐hemolytic streptococci: Clinical significance in the cancer patient
Authors: Pizzo P. A. , Ladisch S. , Witebsky F. G. 
Published: February 2007

AbstractAlpha‐hemolytic Streptococci were associated with 29 episodes of sepsis (12 polymicrobial) in 27 patients with cancer during a nine year period. Only two patients had dental manipulation prior to the onset of sepsis, but each had received chemotherapy and 75% were granulocytopenic (PMN < 500/mm3) at the time of the infection. None of the patients developed bacterial endocarditis. Unlike the normal host in whom a transient bacteria with alpha‐hemolytic Streptococci may occur following dental extraction or periodontal procedures, the cancer patient is at risk for more clinically significant sepsis. This risk is probably related to the presence of chemotherapy‐induced oral mucusitis and granulocytopenia, and our results suggests that isolation of alpha‐hemolytic Streptococci in febrile cancer patients should not be dismissed as a contaminent.
Effects of BCG on peripheral blood counts and drug tolerance of patients with non‐Hodgkin lymphoma receiving combination chemotherapy
Authors: Brooks Robert J. , Jones Stephen E. , Gaines John A. 
Published: February 2007

AbstractPeripheral blood counts and drug dosages were studied in 68 patients with advanced non‐Hodgkin lymphoma, who were assigned at random to receive either chemoimmunotherapy or chemotherapy, in order to determine if Bacillus Calmette Guerin (BCG) immunotherapy lessened myelosuppression or improved drug tolerance. Thirty‐seven patients received CHOP (cyclophosphamide, adriamycin, vincristine, and prednisone) plus BCG, and 31 patients received CHOP plus low‐dose bleomycin. These two treatment groups, similar for important clinical and prognostic factors, were evaluated at courses one, four, and eight of remission induction, by comparison of the following parameters: hemoglobins, hematocrits, platelet counts, white blood‐cell counts (including absolute neutrophil, lymphocyte, and monocyte counts), and dosages of cyclophosphamide and adriamycin. With successive treatment both groups experienced statistically significant progressive declines in the mean values of hemoglobin, hematocrit, total white blood‐cell count, absolute granulocyte and lymphocyte counts, and dosages of adriamycin and cyclophosphamide. These effects of treatment were comparable except for a slightly greater degree of mild anemia in the CHOP‐BCG group (mean hemoglobin ± SEM = 11.7 ± 0.3 gm/dl at course eight compared to 12.7 ± 0.3 gm/dl for the CHOP‐bleomycin group, p = 0.04). Thus, BCG appears to play no beneficial role in lessening myelosuppression resulting from chemotherapy or improving drug tolerance.
In vitro antitumor reactivity of mononuclear leukocytes from cancer patients receiving immunotherapy with BCG
Authors: Mavligit Giora M. , Hersh Evan M. 
Published: February 2007

AbstractMononuclear cell‐mediated cytotoxicity (MCMC) against cultured tumor target cells was studied sequentially in melanoma and breast cancer patients before and during BCG administration. MCMC showed temporary fluctuations. In patients with locally advanced melanoma and carcinoma of the breast after tumor load reduction, the administration of BCG may increase the MCMC. This did not always correlate with a favorable clinical course. Potentiating serum factors appeared in 50% of these patients during BCG therapy, while blocking factors were rare. Neither correlated with prognosis. In patients with disseminated melanoma receiving chemoimmunotherapy, increases in MCMC may be related to clinical course. Blocking serum factors frequently developed in this group of patients and potentiating factors were rare. Neither correlated with the clinical course. Significant MCMC among normal donors and the apparent lack of specificity suggest a common non‐specific (? natural) cellular reactivity against cultured tumor target cells.
Radiation myelitis following craniospinal irradiation with concurrent actinomycin‐D therapy
Authors: Littman Philip , Rosenstock Jeffrey G. , Bailey Clifford 
Published: February 2007

AbstractTwo patients are presented who developed radiation myelitis as a complication of treatment for medulloblastoma. These patients had been entered onto a pilot study to evaluate the therapeutic efficacy of combined treatment with radiation therapy and actinomycin‐D (AMD). AMD is a known radiation enhancer in all tissues but the nervous system. Both of these patients received a full course of cranio‐spinal irradiation plus AMD 15 mcg/kg for the first five days of therapy. One patient developed myelitis at 4 months, and the other at 12 months after treatment. Both patients are surviving three years posttreatment without any evidence of recurrent disease. The myelitis in one patient has improved, and it is stable in the other patient. It is concluded that AMD enhances the effect of radiation therapy on the central nervous system. This has never been reported but is important to note now, since radiation enhancers are included in multimodal treatment regimens for a variety of malignant conditions. Reduction of radiation dose may be necessary when large volumes of the nervous system are treated.
Septicemia in acute leukemia
Authors: Cesario T. C. , Slater L. M. , Armentrout S. A. , Thrupp L. D. , Tilles J. G. 
Published: February 2007

AbstractWe have surveyed septicemic episodes occurring in individuals with acute leukemia and have found two factors favorably influencing survival, mainly granulocyte counts over 1,000 mm3 and gram‐positive bacteremias. In contrast, blood cultures persistently positive for longer than 48 hours were a bad prognosticator. Significantly, patients with gram‐positive bacteremia had received less antibiotics. in the week prior to septicemia than had patients with gram‐negative bacteremia.
The prognostic significance of radiological and symptomatic bone involvement in childhood acute lymphoblastic leukaemia
Authors: Hann Ian M. , Gupta Subash , Palmer Michael K. , Morris‐Jones Patricia H. 
Published: February 2007

AbstractFull skeletal survey was performed on 193 consecutive children presenting over a 6‐year period with acute lymphoblastic leukaemia (ALL). A record was made of the degree of bone pain in these patients and 60 others presenting immediately prior to the availability of skeletal surveys. Bone pain was present in 76 out of 253 patients (30%) and radiological bone changes characteristic of leukaemia in 125 out of 193 (65%). A significant correlation was found between the severity of bone pain and the number of bones involved on × ray (r = 0.25, P = <0.001), but not between initial white cell counts and bone score (r =‐0.14, P = 0.08). There was no significant correlation between the degree of bone pain and survival or length of first remission (P = 0.29 and 0.86). Similarly, the extent of radiological bone disease was of no prognostic significance with relation to survival (P = 0.41) or length of first remission (P = 0.21).
Management of carcinoid syndrome
Authors: Bonomi Philip , Hovey Charlotte , Dainauskas John R. , Slayton Robert , Wolter Janet 
Published: February 2007

AbstractTwo patients who had severe carcinoid syndrome are presented. In one patient prednisone relieved symptoms for 20 months, and in the second patient chemotherapy appears to have precipitated fatal carcinoid crisis. Changes in mentation, increased frequency and intensity of flushing, and hypotension indicate increased risk of a chemotherapy induced carcinoid crisis. Since prednisone may produce relatively long control of carcinoid syndrome, it should be tried before chemotherapy in patients who have increased risk of carcinoid crisis. If chemotherapy is given, doses should be decreased by 50%, and patients should be followed closely.
Chromosomes and causation of human cancer and leukemia: XXXVI. The 14q+ anomaly in an american burkitt lymphoma and its value in the definition of lymphoproliferative disorders
Authors: Kakati Surabhi , Barcos Maurice , Sandberg Avery A. 
Published: February 2007

AbstractA case of a 10‐year‐old boy with American Burkitt lymphoma is presented in whom a 14q+ due to t(8;14)(q23;q32) was shown to exist in the ascitic lymphoma cells. This appears to be the first demonstration of such a translocation in uncultured material. In addition, another translocation involving the × chromosome, hitherto not observed in Burkitt tumors, was demonstrated. The karyotypic findings have been related to the cytogenetic experience in Burkitt and other lymphomas, with emphasis being put on the importance of the 14q+ anomaly in lymphoproliferative diseases.
Localized bone marrow relapse in acute lymphoblastic leukemia
Authors: Golembe Sarry , Ramsay Norma K. C. , McKenna Robert , Nesbit Mark E. , Krivit William 
Published: February 2007

AbstractLocalized bone marrow relapse is rare in acute lymphoblastic leukemia. Discordant bone marrow specimens were found in an 11‐year‐old asymptomatic girl who had been in remission for six years and off chemotherapy for 2 1/2 years. One bone marrow sample showed marked leukemic infiltration, whereas marrow from another site was normal. Three months later, with normal peripheral blood counts, she developed severe back pain and x‐ray evidence of vertebral collapse and periosteal changes in the public bone. At that time three of the four areas of bone marrow sampled showed leukemic involvement. Reinduction therapy was begun, and she is now in remission on maintenance chemotherapy. At this time, it is unclear whether routine performance of marrow aspirations and biopsies from multiple sites, in periodic follow‐up examinations of patients with acute leukemia would allow earlier detection of relapse frequently enough to justify the procedure. The issue of localized bone marrow involvement, if more common than previously reported, should be addressed at the time a decision is being made to discontinue therapy.
Childhood non‐Hodgkin malignant lymphomas: A clinicopathologic retrospective study
Authors: Gasparini Marco , Fossati‐Bellani Franca , Lombardi Fabrizio , Lattuada Angelo , Pilotti Silvana , Rilke Franco 
Published: February 2007

AbstractBetween 1968 and 1975, 44 evaluable children under 16 years of age with the histologic diagnosis of non‐Hodgkin malignant lymphoma (ML) were treated at the Istituto Nazionale Tumori of Milan. Histologic diagnoses were reclassified as follows: 13 lymphoblastic (others) ML, 15 convoluted cell type lymphoblastic ML, 9 Burkitt type ML, and 7 immunoblastic ML. Only 36% of the patients had stage I and II disease. At diagnosis 25% showed malignant cells in the bone marrow smears. Bone marrow infiltration was particularly frequent in the convoluted cell type lymphoblastic ML and in the lymphoblastic (others) ML subgroups. Burkitt type ML frequently was associated with abdominal lesions and subsequently a high incidence of central nervous system involvement. Patients with stage I and II ML were encountered mostly in the immunoblastic ML subgroup. After 1973 more intensive chemotherapy plus radiotherapy seems to have slightly improved the survival of the patients, except in the Burkitt type ML subgroup.
Adenocarcinoma of unknown primary site: A clinico‐pathological study
Authors: Snyder R. D. , Mavligit G. M. , Valdivieso M. 
Published: February 2007

AbstractAn analysis of the clinico‐pathological findings in 49 patients with adenocarcinoma of unknown primary origin indicates a short survival time. No factors were identified that influenced survival. Thromboembolic episodes and second primary tumors commonly complicate the clinical course. Metastases in widespread organs are common autopsy findings. Immunological mechanisms may explain these findings.
Wilms tumor with extension to the right atrium
Authors: Kolmannskog Svein , Moe Peter J. , Besigye Emmanuel , Sørlie Dag 
Published: February 2007

AbstractA seven‐year‐old boy had cardiac symptoms for five months before the diagnosis of Wilms tumor was made. The tumor extended into the inferior vena cava through the renal vein and protruded into the right atrium. All demonstrable tumor masses could be removed at a one‐step surgical procedure without using cardiopulmonary bypass. Intensive postoperative chemotherapy has been given, and 15 months after surgery he was without signs of relapse.
Long‐term survival in childhood acute leukemia: “Late” relapses
Authors: Land Vita J. , Berry Daisilee H. , Herson Jay , Miale Thomas , Ried Hubert , Silva‐Sosa Mario , Starling Kenneth ,   A Southwest Oncology Group Study
Published: February 2007

AbstractThe “late” relapse patterns of childhood acute leukemia were studied in 83 children in their first continuous complete remission for more than three years prior to randomization for stopping therapy (40 patients) or continuing therapy (43 patients) for a total of six years. Twenty of 83 (22.9%) have relapsed: Ten in the bone marrow, one in the central nervous system, and nine in the testes. The testes relapse rate of 41.1% (7/17) in males discontinuing therapy at three years was much higher than that of 8.7% (2/23) in males continuing therapy. This difference is significant at P = 0.01 (Wilcoxon test).
Chronic lymphocytic leukemia in association with a second lymphoproliferative disorder: Response to chemotherapy in two cases
Authors: Gordon Leo I. , Hrushesky William , Oken Martin M. , Kay Neil E. , Rydell Robert E. 
Published: February 2007

AbstractThe development of either histiocytic lymphoma or Hodgkin disease in association with pre‐existing chronic lymphocytic leukemia has been described in the literature as a terminal event. We describe two patients in whom the diagnosis of a second malignant lymphoma was made during life and who achieved objective clinical response after a change in therapy to a more aggressive combination of drugs. We conclude that patients with chronic lymphocytic leukemia who have had a sudden change in their clinical course should have thorough reevaluation, looking specifically for the development of a second lymphoproliferative disorder. If this is discovered, more aggressive therapy should be initiated.
Pyomyositis in acute lymphocytic leukemia heralded by cutaneous vasculitis: Brief communication
Authors: Blatt Julie , Reaman Gregory , Pizzo Philip A. 
Published: February 2007

AbstractWe have observed two cases of staphylococcal myositis in patients with acute lymphocytic leukemia which are distinguished from previously reported cases by a history of cutaneous vasculitis overlying the area of subsequent infection.
Combination radiotherapy and chemotherapy for small cell carcinoma of the lung
Authors: Goldberg R. S. , Joss R. A. , Bedwinek J. , Yates J. W. , Krakoff I. H. 
Published: February 2007

AbstractTwenty previously untreated patients with small cell carcinoma of the lung were treated with cyclophosphamide, 400 mg/m2, and Adriamycin, 40 mg/m2 IV on day 1, followed by cytosine arabinoside, 20 mg/m2, every 12 hours subcutaneously on days 5–9; this regimen was repeated every 28 days. On days 14–28 of the first cycle, each patient received 3,000 rads to the primary tumor and whole brain. Following eleven courses, Adriamycin was discontinued and patients received cyclophosphamide, 800 mg/m2 IV on day 1 and methotrexate, 15 mg/m2 IV on days 5–7. This regimen was repeated every 28 days. Toxicity included nausea, vomiting, alopecia, leukopenia, thrombocytopenia, and esophagitis. Overall response rate was 65%. Median survival in limited disease was 14.5 months, and in extended disease it was 4.5 months. This combination is active in localized small cell carcinoma but provides no superiority over other regimens.
Combination chemotherapy of colorectal cancer with 5‐fluorouracil, methyl‐1,3‐cis(2‐chloroethyl)‐1‐nitrosourea, and vincristine
Authors: Joss Rudolf A. , Goldberg Ronald S. , Yates Jerome W. 
Published: February 2007

AbstractThe combination of 5‐fluorouracil (5‐FU), methyl‐1,3‐cis(2‐chlorethyl)‐1‐nitrosourea (methylCCNU), and vincristine (VCR) has been reported to produce a 43.5% response rate in metastatic colorectal cancer, although subsequent studies did not produce such good response rates. The clinical trial reported here was undertaken to assess the reported results. In 52 evaluable patients the overall response rate was 11%. No complete remissions were observed. Six patients with colon carcinoma had a partial remission lasting for a median of ten months, with a median survival of 15 months. No responses were observed in rectosigmoid cancer. The median survival for nonresponders was 7.5 months. Thirty‐three percent of the patients had significant hematological toxicity (white count ≤ 1,000/mm3, platelets ≤ 50,000/mm3); 58% of the patients experienced nausea and vomiting; and 32% experienced some degree of neurotoxicity. In our hands the combination of 5‐FU, methylCCNU, and VCR produced a response rate of 11% in metastatic colorectal cancer with a considerable amount of toxicity.
Inflammatory fibrous histiocytoma: Response to non‐surgical therapy: A case report
Authors: Smith David K. , Poon Man‐Chiu , Flint Andrew 
Published: February 2007

AbstractA case of inflammatory fibrous histiocytoma arising in soft tissue near the sacrum is presented. The patient's mode of presentation, clinical course, and tumor histology were typical of this disease. The tumor was inoperable, and radiotherapy combined with doxorubicin, cyclophosphamide, and intermediate‐dose oral methotrexate produced a dramatic complete response lasting over 27 months. Favorable results with nonsurgical therapy have not previously been reported for this disease. The gratifying result obtained, although of relatively short duration to date, indicates that combined modality therapy may provide significant back‐up to aggressive surgery. The use of these agents in an adjuvant setting merits study.
Remission induction in acute nonlymphocytic leukemia: Comparison of a seven‐day and ten‐day infusion of cytosine arabinoside in combination with adriamycin
Authors: Preisler H. , Bjornsson S. , Henderson E. S. , Hryniuk W. , Higby D. , Freeman A. , Naeher Carl 
Published: February 2007

AbstractForty‐six previously untreated patients with acute nonlymphocytic leukemia were treated with a remission induction regimen consisting of three daily doses of Adriamycin (30 mg/m2/day) and a ten‐day continuous infusion of cytosine ara binoside (ara C) (100 mg/m2/day). The overall remission rate was 72%, with 88% of the patients < 50 and 62% of patients > 50 years old achieving complete remission status. Thirty‐one of the 33 complete remissions occurred after a single course of chemotherapy. Retrospective comparison of this regimen with its predecessor (identical, except that a seven‐day infusion of ara C was administered) demonstrated that the increase in duration of ara C administration resulted in greater antileukemic effectiveness without an increase in hematologic toxicity to the patient.